Chemoprevention of colorectal cancer with nonsteroidal anti‐inflammatory drugs

10.1136/bmj.321.7264.805

Lee HP, Cancer Incidence in Five Continents

Lee HP, Cancer Incidence in Five Continents

Ochikubo S, Cancer Incidence in Five Continents

Sanada K, Cancer Incidence in Five Continents

10.1056/NEJM200007203430301

10.1016/S0140-6736(96)03386-7

10.1016/S0140-6736(96)03430-7

10.1056/NEJM199305133281901

10.1053/gast.2003.50090

10.1073/pnas.88.7.2692

Fu JY, 1990, The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes, J Biol Chem, 265, 16 737, 10.1016/S0021-9258(17)44821-6

10.1016/0003-9861(92)90411-O

10.1016/S1470-2045(02)00680-0

Watson AJ, 1998, Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX‐1 and COX‐2, Histopathology, 13, 591

10.1073/pnas.95.2.681

10.1056/NEJM200003023420909

10.1016/S0092-8674(00)81433-6

10.2174/1568009033481723

10.1016/0016-5085(94)90246-1

10.1016/S0304-419X(00)00006-8

Kawamori T, 1998, Chemopreventive activity of celecoxib, a specific cyclooxygenase‐2 inhibitor, against colon carcinogenesis, Cancer Res, 58, 409

10.1002/jso.2930240119

Hune GA, 1988, Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study, Cancer Res, 48, 4399

10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D

10.1001/archinte.1994.00420040050009

10.1038/sj.bjc.6600945

10.1038/sj.bjc.6600760

Strul H, 2000, Non‐steroidal anti‐inflammatory drugs and selective apoptotic anti‐neoplastic drugs in the prevention of colorectal cancer: the role of super aspirins, Isr Med Assoc J, 2, 695

10.1023/B:CACO.0000007973.59863.66

10.1136/bmj.320.7250.1642

10.1054/bjoc.1999.1106

10.1002/cncr.10333

10.1093/jnci/85.15.1220

10.1007/BF02088554

10.1056/NEJMoa021735

10.1016/S0016-5085(03)00887-4

10.1053/gast.2002.31890

10.1056/NEJMoa012015

10.1001/jama.284.10.1247

10.1056/NEJM200011233432103

10.1016/S0016-5085(03)00880-1

10.1056/NEJM200006293422603

10.2741/1429

10.1023/A:1026130623186

Higuchi T, 2003, A randomized, double‐blind, placebo‐controlled trial of the effects of rofecoxib, a selective cyclooxygenase‐2 inhibitor, on rectal polyps in familial adenomatous polyposis patients, Clin Cancer Res, 9, 4756

10.1056/NEJMoa021633

Milas L, 2003, Improvement of radiotherapy or chemoradiotherapy by targeting COX‐2 enzyme, Oncology (Williston Park), 17, 15

Petersen C, 2000, Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase‐2 inhibitor, Clin Cancer Res, 6, 2513

Kishi K, 2000, Preferential enhancement of tumor radioresponse by a cyclooxygenase‐2 inhibitor, Cancer Res, 60, 1326

Yamauchi T, 1997, The potential for a selective cyclooxygenase‐2 inhibitor in the prevention of liver metastasis in human colorectal cancer, J Natl Cancer Inst, 89, 1152

10.1016/S0895-4356(03)00131-8

Lin E, 2002, Effect of celecoxib on capecitabine‐induced hand‐foot syndrome and antitumor activity, Oncology (Williston Park), 16, 31

10.1002/ijc.11164

Victor Trial(2002–2004). Available from:http://www.octo‐oxford.org.uk/Trials/victor/victor.aspx. (accessed 15th February 2005)

10.1038/sj.bjc.6690263

10.1093/jnci/89.15.1152

Vioxx.com. Available at:http://www.vioxx.com/rofecoxib/vioxx/hcp/hcp_notification_physicians.jsp.

Rigas B, 2002, NO‐releasing NSAIDs and colon cancer chemoprevention: a promising novel approach, Int J Oncol, 20, 885

10.1016/S0090-6980(02)00003-5

10.1053/gast.2002.29689

10.1016/S0002-9343(03)00095-0

10.7326/0003-4819-135-9-200111060-00007

10.1097/00054725-200307000-00003